Trials / Completed
CompletedNCT00855660
Effect of Riociguat on Bone Metabolism
Investigation of the Effect of Riociguat, Administered as 2.5 mg IR-tablets TID Over 14 Days, on Bone Metabolism in a Randomized, Placebo-controlled, Double-blind, 2-fold Cross-over Design in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Investigation of the effect of Riociguat, administered as 2.5 mg IR-tablets TID over 14 days, on bone metabolism.
Detailed description
Clinical pharmacology
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg | Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days. |
| DRUG | Placebo | Placebo administered as a single tablet, thrice daily, over 14 days. |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-12-01
- Completion
- 2010-07-01
- First posted
- 2009-03-04
- Last updated
- 2016-01-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00855660. Inclusion in this directory is not an endorsement.